Halozyme Therapeutics (MEX:HALO) Moat Score : 5/10 (As of Jul. 04, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Halozyme Therapeutics Moat Score?

Halozyme Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Halozyme Therapeutics has Narrow Moat: Halozyme has a solid narrow moat due to its proprietary drug delivery technology and valuable patents. However, it faces significant competition and lacks the broad market leadership or regulatory barriers needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Halozyme Therapeutics might have Narrow Moat - Solid narrow moat.

Competitive Comparison of Halozyme Therapeutics's Moat Score

For the Biotechnology subindustry, Halozyme Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Moat Score falls into.

Save Embed

;

Save Embed

;

Halozyme Therapeutics (MEX:HALO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Halozyme Therapeutics Moat Score Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (MEX:HALO) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

HALO:USA 1HALO:Italy 0J2O:UK RV7:Germany RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.